Latest News & Updates
Breaking News
2 hours ago
Vaibhavi M.
Other trending news you may like to read
Prelude Therapeutics Signs Exclusive Option Agreement With Incyte For Mutant-Selective JAK2V617F Inhibitor Program
Prelude and Incyte collaborate on a selective JAK2V617F inhibitor program aimed at advancing new treatments for myeloproliferative neoplasms.
Vaibhavi M.
Tonix Pharmaceuticals Collaborates With Massachusetts General Hospital For Phase 2 Study Of TNX-1500 In Kidney Transplant Patients
Tonix teams up with MGH for a Phase 2 trial of TNX-1500 in kidney transplant recipients to test safety and reduce immunosuppressive drug use.
Vaibhavi M.
Merck Secures $700 Million From Blackstone To Advance Sacituzumab Tirumotecan Development
Merck gets $700 million from Blackstone to advance Phase 3 development of sacituzumab tirumotecan for TROP2-expressing cancers.
Vaibhavi M.
Merck Gains Full Global Rights To MK-8690 Following Agreement With Dr. Falk Pharma
Merck secures full global rights to MK-8690 after ending co-development with Falk, recording a $150 million charge in Q4.
Vaibhavi M.
